Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Gentle Sunder, Bista, Bidesh, Dhungana, Ashesh, Poudel, Nimesh, Bhattarai, Shraddha, Shrestha, Manjit, Bhandari, Sandip, Vaidya, Binit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of the Nepal Medical Association 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369566/
https://www.ncbi.nlm.nih.gov/pubmed/34508399
http://dx.doi.org/10.31729/jnma.6680
_version_ 1783739318964060160
author Shrestha, Gentle Sunder
Bista, Bidesh
Dhungana, Ashesh
Poudel, Nimesh
Bhattarai, Shraddha
Shrestha, Manjit
Bhandari, Sandip
Vaidya, Binit
author_facet Shrestha, Gentle Sunder
Bista, Bidesh
Dhungana, Ashesh
Poudel, Nimesh
Bhattarai, Shraddha
Shrestha, Manjit
Bhandari, Sandip
Vaidya, Binit
author_sort Shrestha, Gentle Sunder
collection PubMed
description Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.
format Online
Article
Text
id pubmed-8369566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Journal of the Nepal Medical Association
record_format MEDLINE/PubMed
spelling pubmed-83695662021-08-30 Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report Shrestha, Gentle Sunder Bista, Bidesh Dhungana, Ashesh Poudel, Nimesh Bhattarai, Shraddha Shrestha, Manjit Bhandari, Sandip Vaidya, Binit JNMA J Nepal Med Assoc Case Report Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers. Journal of the Nepal Medical Association 2021-06 2021-06-30 /pmc/articles/PMC8369566/ /pubmed/34508399 http://dx.doi.org/10.31729/jnma.6680 Text en © The Author(s) 2018. https://creativecommons.org/licenses/by/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Shrestha, Gentle Sunder
Bista, Bidesh
Dhungana, Ashesh
Poudel, Nimesh
Bhattarai, Shraddha
Shrestha, Manjit
Bhandari, Sandip
Vaidya, Binit
Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title_full Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title_fullStr Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title_full_unstemmed Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title_short Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report
title_sort tofacitinib as an adjunct immunomodulator for treatment of a patient with severe covid-19: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369566/
https://www.ncbi.nlm.nih.gov/pubmed/34508399
http://dx.doi.org/10.31729/jnma.6680
work_keys_str_mv AT shresthagentlesunder tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT bistabidesh tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT dhunganaashesh tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT poudelnimesh tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT bhattaraishraddha tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT shresthamanjit tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT bhandarisandip tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport
AT vaidyabinit tofacitinibasanadjunctimmunomodulatorfortreatmentofapatientwithseverecovid19acasereport

Ejemplares similares